spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Bezyl, Inc. and THREAD Form Strategic Partnership to Support the Mental Health of Clinical Trial Participants

Thread




Phoenix, AZ (May 31, 2022) — Bezyl, Inc., a global, digital mental health company, announced today that it is collaborating with THREAD® to provide its mental health digital app and support system to patients participating in clinical trials. Grounded within a secure communications platform, the Bezyl app makes it easier for patients to ask for help from friends, family, and caregivers. Additionally, it provides access to useful and easy-to-navigate resources specific to the patients’ needs. With the Bezyl app, patients can easily request help from their network, set check-ins and reminders, and track their moods. As a peer-support tool, the Bezyl app aims to help patients eliminate anxiety, retain their participation in clinical trials, maintain treatment compliance, and most importantly, build their mental strength.

Founder and CEO of Bezyl, Inc., Esther Howard, shared her personal inspiration behind the development of the Bezyl app: “One of my best friends, who had a young daughter, a beautiful family and set of friends, died of colon cancer. During her illness, her family and friends always wanted to do more to support her through her treatment, and she had wished it was easier to ask for help when she needed it. She was referring to the simple things in life, like reading to her daughter or taking her to a doctor’s appointment, or even just sitting down and having tea with her on the days that she was feeling better.” Moved by the words from her friend, Esther set out to find a way to make seeking and receiving help easier and, in turn, build mental strength in a world that so desperately needs it.

As part of this new partnership, THREAD will offer the Bezyl mental health app to study sponsors as an optional solution provided directly by Bezyl. THREAD, the industry’s leading provider of decentralized clinical trials (DCTs) and eCOA, is enabling studies to be more inclusive, patient-centric and efficient. Bezyl’s digital mental health solution adds to THREAD’s offerings by providing a novel tool aimed at supporting mental health and connection throughout the life cycle of a study.

“We recognize that supporting participants in clinical trials requires a multi-faceted approach. Supporting the mental health of study participants is important to our customers, sites, study teams, and THREAD,” said John Reites, CEO, THREAD. “We are proud to offer Bezyl to our customers as a secure and unique solution to support mental health.”

“Our ultimate mission is to end the global mental health pandemic by helping people help each other,” said Esther Howard, founder and CEO, Bezyl, Inc. “Patients participating in clinical research, especially cancer patients, can benefit from realizing the full strength from their network of supporters.”

The Bezyl team will be among the more than 40,000 oncology professionals convening in Chicago and virtually for the 2022 ASCO Annual Meeting from June 3-7.

In addition to supporting patients, earlier this month, Bezyl released a Ukrainian-specific version of its app to help Ukrainians build personal networks of support and find access to much needed humanitarian relief.

About Bezyl
Bezyl is the only global, digital mental health company that provides a simplified communication platform to help people help each other improve their mental strength. Asking for help is easier using Bezyl’s proprietary technology that directly connects individuals to their designated spheres of support.
Learn how the app works at bezyl.com.

About THREAD
THREAD® is the industry-leading decentralized clinical trials technology and consulting service provider, helping biopharma and CROs decentralize clinical research and enable electronic clinical outcome assessments (eCOA) for sites, participants, caregivers, and home health professionals. Through its end-to-end unified platform, THREAD is making studies 30 percent more efficient and five times more inclusive and diverse. Backed by health care investors Water Street Healthcare Partners and JLL Partners, THREAD is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021, Frost & Sullivan’s 2021 Customer Value Leadership Award as well as a long list of accolades.
Visit THREADresearch.com to learn more.

Media Contacts:
Esther Howard
Founder & CEO, Bezyl, Inc.
+1 434 409-4232
contact@bezyl.com

Jennifer Cosenza
 Catalytic Agency on behalf of THREAD
jennifer.cosenza@catalyticagency.com
phone (866) 392-4788
email info@threadresearch.com
web https://www.threadresearch.com/
email 155 El Camino Real Tustin, CA 92780
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Blood Tests May Prevent Relapse in Breast Cancer Patients

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients will relapse, years before it’s shown on a scan - treatment can then be altered to try and prevent relapse from happening. There are currently no effective tests to establish which patients are at risk of relapse after previous treatment for breast cancer.
More info >>


White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement